Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor
A specific crystalline mesylate salt form of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate, and the use of the same in medicine. (Formula (I)).
1. Crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate salt having the space group P2(1)2(1)2(1), and unit cell dimensions substantially as follows:
a
8.75780(10)Å
α
90°
b
9.70830(10)Å,
β
90°,
c
20.6736(2)Å,
γ
90°.
2. Crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate salt having an XRPD pattern containing the following 2θ value measured using CuKα radiation: 21.948.
3. The salt according to claim 2 having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744 and 21.948.
4. The salt according to claim 2 having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744, 20.886, 21.948.
5. The salt according to claim 2 having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744, 20.886, 21.948, and 9.851.
6. The salt according to claim 2 having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744, 20.886, 21.948, 9.851 and 16.280.
7. The salt according to claim 2 having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 9.851, 16.280, 17.097, 17.744, 19.694, 20.443, 20.886, 21.948, 22.112, 23.194, 23.653, 24.144, 27.084, 27.283 and 29.912.
8. The salt according to claim 2 having an XRPD pattern as set out in Table 4 and/or FIG. 2 .
9. A salt according to claim 1 having a purity of greater than 95%.
10. A salt according to claim 1 having a purity of greater than 99%.
11. A salt according to claim 1 having a purity of greater than 99.5%.
12. A salt according to claim 1 having an enantiomeric purity of greater than 95%.
13. A salt according to claim 1 having an enantiomeric purity of greater than 99%.
14. A salt according to claim 1 having an enantiomeric purity of greater than 99.5%.
15. A pharmaceutical composition comprising a salt according to claim 1 , and one or more suitable excipients.
16. A process of making crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate salt by forming the mesylate salt from the free base of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate.
17. A process according to claim 16 wherein the mesylate salt is formed by addition of methanesulphonic acid to the free base.
18. Crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate obtained by the process according to claim 16 .